To the Editor.—
The recent article by Vance et al1 in the March issue of the Archives, concerning their success in treating condylomata acuminata, but reporting their disappointing results in treating verruca plantaris, using intralesional recombinant α2-interferon therapy, prompted me to briefly present my experience in treating cutaneous nongenital viral warts (CNGVW) with intralesional human lymphoblastoid interferon a and to comment on the results reported by these authors.Following an encouraging pilot study in patients with common and/or plantar viral warts,2 a further exploratory study was established. The aims were to maximize the efficacy and patient acceptability of a treatment regimen based on intralesional injections of human lymphoblastoid interferon a (Wellferon, Wellcome Foundation Ltd) while minimizing the well-known potential for systemic toxicity possessed by the interferons.Fully informed, adult patients of either sex with severe CNGVW present for a minimum of one year, and resistant to
Gibson JR. Intralesional Human Lymphoblastoid Interferon Alpha for the Treatment of Cutaneous, Nongenital Viral Warts. Arch Dermatol. 1986;122(10):1098–1099. doi:10.1001/archderm.1986.01660220012003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: